RxDoctor Payments Data

Kimberly Gibson

Nurse Practitioner · Pass Chris, MSNPI 1699322024

Payments from drug & device makers

$1,363in general payments, 2019–2025

Across 45 payments — averaging $30.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$716
  • AbbVie$249
  • Johnson & Johnson$123
  • Lilly USA, LLC$67
  • Pfizer$52
  • Amgen$44
  • plus $113 from 6 others

What the payments were for

  • Food & beverage$1,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,363 in reported general payments places this provider in the 75th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$33,873
Medicare patients
198
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$92,938
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$62,492
JardianceEmpagliflozin31$49,203
MounjaroTirzepatide39$40,980
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$19,893
JanuviaSitagliptin Phosphate13$16,277
Tresiba Flextouch U-200Insulin Degludec17$15,575
FarxigaDapagliflozin Propanediol14$13,108
TradjentaLinagliptin14$11,112
Albuterol Sulfate HfaAlbuterol Sulfate164$4,324
SynthroidLevothyroxine Sodium32$2,736
Varenicline Tartrate13$2,229
Novolog FlexpenInsulin Aspart16$2,180
Duloxetine Hcl64$2,009
Atorvastatin Calcium254$1,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$92,93876 claims
Lilly USA, LLCMounjaro$67$40,98039 claims
AstraZenecaBreztri Aerosphere, Farxiga$716$33,00136 claims
AbbVieSynthroid$249$2,73632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Pass Chris

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →